我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
25
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1988
进行中（未招募）
1
4.0%
已完成
9
36.0%
尚未招募
2
8.0%
招募中
10
40.0%
Unknown
3
12.0%
暂无批准数据
- Two major Korean university hospitals have received therapeutic use approval for cenobamate in epilepsy treatment, marking the first medical team applications for this indication since SK Biopharmaceuticals' 2022 approval. - Dong-A ST has submitted a domestic product license application for cenobamate, aiming for market launch and reimbursement in 2026 across 30 countries including Korea and various Asian markets. - Cenobamate, marketed as XCOPRI in the US, has demonstrated superior efficacy compared to existing treatments and has been prescribed to over 140,000 patients, offering hope for drug-resistant epilepsy cases.
